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Inflammation is part of the body’s immune response in order to remove harmful
stimuli—like pathogens, irritants or damaged cells—and start the healing process.
Recurrent or chronic inflammation on the other side seems a predisposing factor for
carcinogenesis and has been found associated with cancer development. In chronic
pancreatitis mutations of the cationic trypsinogen (PRSS1) gene have been identified as
risk factors of the disease. Hereditary pancreatitis (HP) is a rare cause of chronic pancreatic
inflammation with an early onset, mostly during childhood. HP often starts with recurrent
episodes of acute pancreatitis and the clinical phenotype is not very much different from
other etiologies of the disease. The long-lasting inflammation however generates a tumor
promoting environment and represents a major risk factor for tumor development This
review will reflect our knowledge concerning the specific risk of HP patients to develop
pancreatic cancer.
Keywords: cancer risk, pancreatitis, hereditary pancreatitis, PRSS1, chronic inflammation
INTRODUCTION
Chronic pancreatitis (CP) and carcinoma of the pancreas are
common in Western countries. Incidence rates of CP range from
2 to 23 per 100,000 and are around 10 per 100,000 for the inci-
dence and death rate of pancreatic cancer (Dufour and Adamson,
2003; Lévy et al., 2006; Ferlay et al., 2010; Spanier et al., 2013).
However, not all CP develops into cancer, even not in the very
long-standing cases, and the majority of patients presenting with
pancreatic carcinoma have no history of CP.
In a recent pooled analysis by the International Pancreatic
Cancer Case-Control Consortium (PanC4) Duell et al. reviewed
a total of 5048 cancer cases and 10947 controls. Interestingly, only
6.2% of pancreatic cancer patients reported a history of pancreati-
tis. Duell et al. calculated a ∼5.6-fold increased pancreatic cancer
risk in patients with a history of pancreatitis (Duell et al., 2012).
In the first two years following diagnosis of pancreatitis, the risk
is even higher (OR: 13.6), probably reflecting increased likelihood
of cancer diagnosis in people undergoing medical investigations,
and possible misdiagnosis of pancreatic cancer as pancreatitis.
The type of pancreatitis was not determined in most of the eval-
uated studies, preventing a more detailed analysis of the specific
risk of acute vs. CP.
Much more than a single inflammatory event, the recurrent
or persistent chronic inflammation is regarded as an important
risk factor for cancer development, not only in the pancreas, but
in many different organs (Mantovani et al., 2008). Observations
that tumors often arise at sites of chronic inflammation were first
made in the nineteenth century (Balkwill and Mantovani, 2001).
Since that time several lines of evidence, based on histologic find-
ings of inflammatory cells in tumor samples and also genetic
and molecular analyses have supported the general concept that
inflammation and cancer are linked. In addition, epidemiologic
studies have shown that chronic inflammation is associated with
the development of several types of cancer. Factors that drive the
chronic inflammation process are many-fold and include toxins
like cigarette smoke, alcohol, microbial infection (helicobacter
pylori), autoimmune diseases (M. Chron), inflammatory con-
ditions of unknown origin, a genetic predisposition (hereditary
pancreatitis) or a combination of several factors.
Numerous studies which analyzed the pancreatic cancer risk
of CP patients reported considerably different results, probably
reflecting methodological variation concerning the recruitment,
diagnosis and evaluation of patients. This review will mainly
focus on the question if pancreatic cancer is especially frequent
in those patients that are predisposed to CP by the presence of a
PRSS1 mutation.
HEREDITARY PANCREATITIS
Hereditary pancreatitis is a rare cause of CP with an estimated
frequency of 0.3 /100.000 in Western countries. In 1952, Comfort
and Steinberg reported a family with hereditary CP over three
generations. Affected patients had chronic relapsing pancreatitis
with an unusual early onset of the disease (5–23 years) (Comfort
and Steinberg, 1952). In 1996 Whitcomb et al. identified from
a large HP family with an autosomal dominant inheritance pat-
tern a first genetic defect of the cationic trysinogen gene (PRSS1)
through sequencing analysis of the 7q35 chromosome region.
They identified a G to A transition in exon 3 of the PRSS1
gene that encodes the replacement of Arginine 122 by Histidine
(Whitcomb et al., 1996). Trypsins are digestive enzymes that
are synthesized and secreted in large amounts by the acinar
cells of the exocrine pancreas. Three different trypsinogen iso-
forms are known and cationic trypsinogen represents 2/3 of the
total amount of trypsinogen in the pancreatic juice. Anionic
trypsinogen accounts for another 1/3 of the trypsinogen, whereas
mesotrypsin is expressed only in small traces. Trypsinogens are
synthesized as enzymatically inactive pro-enzymes or zymogens
that are stored and released from the secretory compartment of
the acinar cell. Under physiological conditions trypsinogens are
activated in the duodenum by enterokinase, which is produced by
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cells of the duodenal mucosa and which cleaves the N-terminal
activation peptide bond and releases the enzymatic activity of
trypsins. Trypsin is the main digestive enzyme of the gastroin-
testinal tract and has autoactivation as well as autolysis properties.
Influenced by ambient pH and calcium concentration the protein
may therefore either tend to self-activation or self-destruction.
Subtle changes in the trypsin protein structure seem sufficient
to disrupt the mechanism of normal trypsin activation lead-
ing to increased premature intrapancreatic trypsin activation or
impaired inactivation. Both ways PRSS1 mutations may lead
to enhanced trypsin activity which eventually increases the risk
for recurrent pancreatic injury and inflammation. Since 1996
more than 30 different PRSS1 mutations have been identified
(www.uni-leipzig.de/pancreasmutation). The majority of these
mutations were reported only in one or a few families and the
biochemical analysis of these mutations gave valuable insights
in the disease mechanism. Some mutations like K23R, D22G,
or D19A are localized in the area where enterokinase activation
of trypsinogen occurs. These mutations were found to facilitate
trypsin autoactivation (Geisz et al., 2013).
Autoactivation of cationic trypsinogen is also influenced by
chymotrypsin C (CTRC), which opposes the trypsin activity
by promoting trypsinogen and trypsin degradation (Szmola
and Sahin-Tóth, 2007). Chymotrypsin C selectively cleaves the
Leu81-Glu82 peptide bond within the Ca2+ binding loop of
cationic trypsin. Further degradation and inactivation is then
achieved through tryptic cleavage of the Arg122-Val123 peptide
bond. Therefore, mutation of either Leu81 or Arg122 blocks
chymotrypsin C-mediated trypsin degradation (Szabó and Sahin-
Tóth, 2012). The mechanistic basis of increased trypsinogen
activation involves either resistance to degradation (N29I, N29T,
V39A, R122C, and R122H) and/or increased N-terminal process-
ing by CTRC (A16V and N29I). In hereditary pancreatitis the
CTRC-dependent control of cationic trypsinogen autoactivation
is disturbed giving rise to intrapancreatic trypsinogen activation.
Most frequent PRSS1 mutations R122H and N29I lead with high
penetrance (∼80%) to CP, in most cases with an early onset of
symptoms. The A16V and R122C mutants were found to have
a more variable disease penetrance ∼40–50% (De Las Heras-
Castaño et al., 2009; Grocock et al., 2010). Apart from some
variation in disease penetrance the clinical phenotypes of these
most relevant HP mutations seem rather comparable and—with
the exception of an early onset—resemble the same features of CP
of other etiologies.
Lowenfels and colleagues from the International Hereditary
Pancreatitis Study Group were one of the first to review the med-
ical records of 246 patients with a diagnosis of HP. Comparison
of observed and expected frequency of cancer in this historical
group of patients revealed and standardized incidence ratio (SIR)
of pancreatic cancer of 53 (95%CI: 23–105). In those individ-
uals that developed pancreatic cancer the mean age at onset of
symptoms of pancreatitis was 17.3 ± 6.9 years and mean age
at diagnosis of pancreatic cancer was 56.9 ±11.2 years, indicat-
ing a high risk of pancreatic cancer several decades (39.6 ± 9.7
years) after the initial onset of pancreatitis(Lowenfels et al., 1997).
The risk was not different in males or in females or for different
nationalities and the cumulative risk in these patients until the
age of 70 was 40%. The diagnosis of HP in the study was mainly
based on early onset of pancreatitis, a positive family history and
the absence of other known causes of pancreatitis. Today we know
that many HP patients have an underlying causative PRSS1muta-
tion, but at the time of the study by Lowenfels the genetic testing
for PRSS1 had only just started and therefore could not yet be
systematically analyzed.
Such a genotype-phenotype correlation was done in 2004 by
Howes et al. on behalf of the European registry of hereditary
pancreatitis and pancreatic cancer (EUROPAC) (Howes et al.,
2004). Their study cohort comprised 112 families (418 individ-
uals) from 14 countries and included 52% R122H-families, 21%
N29I-families, 4% A16V-families and 19% without detectable
mutation. The high mutation rate of 81% in HP was much
higher than previously reported and presumably due to the strict
diagnostic criteria of HP by the EUROPAC group. The authors
confirmed that onset of symptoms starts at young age for R122H
mutation carriers with a median onset at 10 (95%CI: 8–12) and
14.5 (95%CI: 10–21) for mutation negative patients. Interestingly
time to development of exocrine and endocrine failure showed no
significant differences, neither by mutation status nor by gender.
Still the cumulative risk for exocrine failure or diabetes is much
higher in HP (60.2 and 68.6%) than in idiopathic or alcoholic
pancreatitis patients. Pancreatic cancer was diagnosed in 26 (6%)
patients and arose in individuals carrying any of the common
mutations as well as in PRSS1-mutation negative families (14x
R122H, 7x N29I, 1x A16V and 4x no PRSS1 mutation). The time
to develop cancer was not influenced by mutation status, gender
or if the mutation was transmitted from the father or the mother.
The study further showed that the cumulative risk of pancreatic
cancer is rather negligible until the age of 50 (3.4%) in both sexes.
However, after 50 years the risk of pancreatic cancer rises con-
siderably, reaching 18.8% at 70 years and 33.3% at 80 years. In
other words: the cumulative risk of pancreatic cancer after onset
of symptoms slowly increases from 1.5% at 20 years and 2.5% at
30 years after first symptoms to 25.3% at 60 years and 44% at 70
years after the onset of the disease. The calculated SIR of pan-
creatic cancer in the EUROPAC cohort after correction for age,
smokers, nationality and surgical intervention, was 67 (95%CI:
50–82).
In a national series in 2008 Rebours et al. investigated the
SIR of pancreatic adenocarcinoma in an exhaustive cohort of
French HP patients (Rebours et al., 2012). In their nation-wide
survey genetic laboratories, pediatricians and gastroenterologists
contributed 200 individuals from 78 families with know PRSS1
mutation or the diagnosis of recurrent acute or CP in the absence
of known precipitating factors. PRSS1 mutations were present
in 68% (78% R122H, 12% N29I, 10% others) of the study
cohort and again the PRSS1 mutation type did not correlate
with the development of pancreatic cancer, which was diagnosed
in ten individuals at a median age of 55. The cumulative risk
at age 50 was ∼10% and increased to ∼50% at age 75. The
SIR of pancreatic cancer in the French cohort was 87 (95%CI:
42–113) for the whole population and seemed higher in females
(142; 95%CI: 38–225) compared to males (69; 95%CI: 25–150).
Whereas Lowenfels et al. also found a slightly higher SIR in
females (73 vs. 46) the results from the EUROPAC study indicated
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a higher SIR in men (72 vs. 60). A gender impact therefore
seems not generally operative in the development of pancreatic
adenocarcinoma.
In comparison to the general population HP patients clearly
carry an increased absolute risk of developing pancreatic cancer.
Smoking was identified as a main associated risk factor and HP
patients therefore should be strongly advised to stay away from
tobacco consumption. Diabetes and calcifications are also more
frequently seen in patients that develop pancreatic cancer, prob-
ably indicating a correlation of the cancer risk not only with the
duration but also with the severity of pancreatitis.
PANCREATIC CANCER RISK IN SPORADIC PANCREATITIS OF
MUTATION CARRIERS
In the clinical situation HP is diagnosed mainly in patients with
idiopathic recurrent acute or CP families. However, sometimes
also sporadic cases without a corresponding family history have
a positive finding of an HP mutation. Inheritance from unaf-
fected carrier parents, uncertain paternity and spontaneous de
novo mutations must be considered in such cases (Simon et al.,
2002). A recent study by Hamoir et al. identified a total of 17.4%
carriers of CFTR, PRSS1, or SPINK1mutations in a cohort of 351
Belgium patients with idiopathic recurrent or CP and no family
history (Hamoir et al., 2013). The authors claim that the clinical
features were not influenced by the presence of a gene mutation
except for an earlier age at onset and a higher incidence of pan-
creatic cancer, especially in patients with a CFTR mutation (four
cancer patients had CFTR mutations, one a PRSS1 mutation).
The SIR for pancreatic cancer in their cohort was 26.5 (95%CI:
8.6–61.9). However, all cancer patients were also smokers. The
authors suggest to “include patients with CFTR variants present-
ing with risk factors in a screening and surveillance program and
to strongly advise them not to smoke.” Three of the four can-
cer patients with CFTR mutation carried the p.L997F mutation
(2× compound heterozygous, 1× heterozygous) which also had
been identified at high frequency in patients with recurrent idio-
pathic pancreatitis (Gomez Lira et al., 2000). Whereas there is no
disagreement concerning the adequacy of a non-smoking advice
other reports find a modest increased risk for carriers of disease-
relevant CFTR mutations (OR:1.4; 95%CI: 1.04–1.89) and are
more reluctant concerning the role of CFTR mutations as risk
factors of pancreatic cancer (Whitcomb, 2004; McWilliams et al.,
2010).
CHRONIC INFLAMMATION AND CANCEROGENESIS
The link between CP and pancreatic cancer is unknown to date,
but several signaling pathways were identified to become activated
in the inflamed pancreas which may trigger cellular transfor-
mation and ultimately stimulate the development of pancreatic
cancer.
It is generally accepted that inflammation results in repeated
DNA damage, error-prone repair-mechanisms and the pro-
gressive accumulation of genetic mutations. In the pancreas
pre-cancerous histologic changes have been described that are
associated with a sequential accumulation of genetic defects.
These pancreatic intra-epithelial neoplasms (PanIN) are present
in sporadic pancreatic adenocarcinomas and also in patients
with a history of CP. Histologically, PanINs progress through
stages of increasing architectural and cytological atypia, start-
ing from a low grade dysplasia (PanIN-1A, PanIN-1B) to
moderate dysplasia (PanIN-2) and to high grade dysplasia
(PanIN-3). First genetic mutations seen in the early stages
include kRas mutations, followed by p16/CDKN2A, TP53, and
SMAD4/DPC4 (Hruban et al., 2004). Mutations in all four
genes have been recognized as driver mutations that trigger
neoplastic transformation and tumor progression (Korc, 2010).
In a mouse model kRas mutations were shown to give rise
to pancreatic intraepithelial neoplasms and pancreatic can-
cer and that concomitant mutation of p16, p53 or smad4
greatly enhanced the process of carcinoma formation (Hingorani
et al., 2005). These mutations are more frequent in advanced
PanIN stages and are well-characterized in invasive pancreatic
carcinoma.
Signaling mechanisms involving Hedgehog and Notch, as
well as cyclooxygenase 2 (COX-2) have also been implicated
in the triggering mechanisms that stimulate the generation of
pancreatic cancer from pancreatic inflammation (Maitra et al.,
2002; Avila and Kissil, 2013; Hamada et al., 2013). COX-
2 mediates prostaglandine synthesis which triggers cell pro-
liferation and cytokine synthesis. Cox-2 inhibitors have been
demonstrated to have anti-cancer effects and are effective
especially in patients with cancers that have a high COX-2
expression. Extensive inflammation exposes the organ tissue to
pro-inflammatory cytokines and reactive oxygen species. Local
production of both may activate cellular protective mechanisms,
including apoptosis and regenerating mechanisms that stimu-
late cell proliferation in order to rebuild the lost tissue structure.
Increased proliferation in the presence of elevated concentra-
tions of potential mutagens such as reactive oxygen species may
set an environment where growth promoting mutations accu-
mulate and provide selective growth advantage for individual
cell clones.
Another signaling pathway that has been suggested to drive
cancerogenesis from inflammation involves NFkB (Karin, 2006).
Important cancer-associated genes, such as c-myc, jun B Cyclin
D1, TP53, and VEGF are under the control of this transcrip-
tion factor. In addition it’s a major factor controlling the ability
of malignant cells to resist apoptosis-based tumor-surveillance
mechanisms.
PERSPECTIVE
PANCREATIC CANCER SURVEILLANCE
Today there is no rationale for early diagnostic screening of pan-
creatic cancer in the general population. It’s a rare disease, specific
diagnostic markers are missing and a survival benefit of such
screening programs has nowhere been demonstrated. However,
pancreatic cancer screening is recommended for families and
individuals at an elevated risk. Counseling and surveillance guide-
lines have been established that recommend screening studies as
part of peer-reviewed protocols with scientific evaluation and
human subjects protection(Brand et al., 2007). Candidates for
pancreatic cancer surveillance should carry a >10-fold increased
risk for developing pancreatic cancer, which includes individuals
with HP.
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SURGERY
Generally, the survival rate for patients with CP is poor (Jupp
et al., 2010). CP patients tend to die of other causes such as
smoking related cancers, cardiovascular disease and alcoholic
liver cirrhosis. The potential cancer risk of a persistent inflamma-
tion may suggest beneficial effects of anti-inflammatory therapy
or surgery for CP. A recent retrospective multicenter study from
Japan investigated associated factors with the pancreatic cancer
risk in 506 patients with CP (Ueda et al., 2013). Nineteen of 506
enrolled patients developed pancreatic cancer (3.7%) with a SIR
of 11.8 (95% CI, 7.1–18.4). Interestingly, among 9 patients with
HP, no patient developed pancreatic cancer (follow-up period:
3.4–43.8 years, median, 8.4 years). Among the 352 CP patients
who had not received surgical treatment a total of 18 patients
(5.1%) developed pancreatic cancer, which otherwise occurred in
only 1 (0.7%) of the 147 patients who had undergone surgery
for CP. Apparently surgery for CP inhibits the development of
pancreatic cancer in those patients.
In addition the study confirmed that patients who continued
to drink alcohol after the diagnosis of CP showed a significant
higher incidence of pancreatic cancer than those who stopped
drinking.
BIOMARKER
The goal for diagnostic screening is the identification of early can-
cer lesions before the onset of metastasis and tissue invasion. Until
today no biomarker in plasma or serum has generally been rec-
ommended for screening or diagnosing of pancreatic cancer and
there is an urgent need to identify novel markers of pancreatic
cancer. The search is on for new strategies that help to improve
the sensitivity and specificity of diagnostic procedures.
One example is a study of Yokoi et al. who analyzed proteins
from circulating mononuclear cells (MNC) to identify surrogate
markers of pancreatic cancer (Yokoi et al., 2011). Continuous
interactions between tumor cells and host stroma cells is a funda-
mental requirement for tumor cell growth, invasion, andmetasta-
sis (Fidler et al., 2007). In histologic stainings the stroma typically
occupies 70–90% of pancreatic tumors. Among the cellular com-
ponents of the stroma, MNCs are believed to play a central role
in the progression and chemoresistance of tumors (Condeelis
and Pollard, 2006; Noonan et al., 2008). Circulating MNCs, such
as monocytes and/or macrophages, are recruited into the tumor
microenvironment, where they extravasate and differentiate into
tumor-associated macrophages (TAMs) (Shojaei et al., 2008).
Even small tumors could generate a detectable immune response
that may include changes in protein content or phosphorylation
of MNCs. Analysing circulating MNCs in a nude mouse model of
orthotopic human pancreatic cancer, Yokoi et al. found significant
higher Src-expression (c-src tyrosinkinase) and phosphorylation
in MNCs from mice bearing tumors. The identified surrogate
marker Src may not be a convincing finding so far, but circulating
MNCs may represent a good source for the identification of novel
biomarkers of early tumor development.
In summary HP markedly increases the risk for pancreatic
adenocarcinoma. PRSS1 and other pancreatitis-associated gene
mutations are not directly important in the development of pan-
creatic cancer, but rather lead to a high-risk inflammatory milieu
for the accumulation of oncogenic mutations. The risk is poten-
tiated by known cofactors such as tobacco smoking and, likely,
by genetic factors that are yet to be identified. Future genetic
and molecular studies will help to a better understanding of the
relationship between inflammation and cancerogenesis and may
lead to new diagnostic and therapeutic possibilities for those
subjects with CP that are at high risk of developing pancreatic
carcinoma.
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